Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EOP1
- Development stage
- Preclinical
- Lead developer
- The Christie
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
EOP1 is a first-generation vaginal pessary developed to alleviate symptoms of urogenital atrophy (UA) in breast cancer survivors, particularly those undergoing endocrine therapy. It is formulated with a cocoa butter base and contains three plant extracts/essential oils: CM, PG, and CO, each at a 1% volume/volume concentration. Initial evaluations indicated its effectiveness in reducing UA symptoms. However, subsequent in vitro studies revealed that two of its components, CM and PG, exhibited significant estrogenic activity, raising safety concerns for patients with estrogen receptor-positive breast cancer.
- Other names
- first-generation essential oil pessary
02
Targets
ER (Estrogen receptor)
Beyond the preview
Go deeper on EOP1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EOP1.